Detection And Analysis Of Plasma Concentrations Of Adiponectin In Men With Acute Coronary Syndrome

Objective: To explore the plasma level of adiponectin in men with acute coronary syndrome (ACS), and also to analyse the relationship between plasma concentrations of adiponectin and number of diseased vessel, different condition types and risk factor in coronary artery disease (CAD).Methods: Sixty-four men with chest pain in hospital diagnosed as ACS, were envolled in this study. According to different clinical manifestation, they were divided into acute myocardial infarction (AMI) group (n=33), unstable angina pectoris (UAP) group (n=31). After coronary angiography (CAG) or multi-slice spiral CT (MSCT), the 64 cases were also divided into three groups according to the number of diseased vessel: one-vessel group (n=24); two-vessel group (n=18); three-vessel group (n=21). There were 41 healthy controls in this study. Fasting plasma adiponectin was assayed by radioimmunoassay, and related parameters such as blood pressure, body mass index (BMI), fasting blood glucose, lipids etc. SPSS11.5 was used for statistical analysis, the quantitative data were written as mean±standard deviation (±s), student t test and F test was used for data comparison, p<0.05 means significant difference. Correlations between plasma concentrations of adiponectin and the value of other parameters were examined by Pearson's coefficient of correlation. Correlations between ACS and all other parameters were analysed by multivariate logistic regression analysis.Result: (1) Plasma concentrations of adiponectin in men with ACS [8.56±3.82mg/L], in both the AMI and UAP groups, were significantly lower than those in the control group [12.95±4.36mg/L, p<0.01]. The plasma concentrations of adiponectin in the AMI group were not significantdifference than those in the UAP group (p>0.05). (2 ) Plasma concentrations of adiponectin in three, two and one-vessel group were [6.69±3.08mg/L], [8.32±3.36mg/L] and [9.32±4.53mg/L], respectively. Plasma concentrations of adiponectin in one, two and three-vessel group were significantly lower than those in the control group [12.95±4.36mg/L, p<0.01]. Plasma concentrations of adiponectin in three-vessel group were significantly lower than those in one-vessel group (p<0.05). Plasma concentrations of adiponectin in two-vessel group were not significant difference than one-vessel group (p>0.05). (3) Plasma adiponectin level was negatively correlated with BMI (r=-0.39, p<0.01), and serum triglyceride (TG) level( r=-0.36, p<0.01 ) , while positively correlated with high density lipoprotein cholesterol (HDL-ch)(r=0.29, p<0.01).Total cholesterol (TC) concentrations and low density lipoprotein cholesterol (LDL-ch) concentrations did not correlate with plasma concentrations of adiponectin. (4) By multivariate logistic stepwise regression analysis, an equation was founded:㏑[P/(1-P)]=-28.335 +0.208X1 + 0.744X2 + 3.132X3 -0.326X4 (p< 0.01). The equation demonstrated that BMI (X1), TG (X2), age (X3) and adiponectin (X4) play a role in the development of ACS (p<0.01),and adiponectin is a protector of ACS.Conclusions: (1) Measurement of plasma concentrations of adiponectin may be an independent risk factor in coronary artery disease. (2) Plasma level of adiponectin may be related to the development of ACS and may be used to assess the severity of coronary artery stenosis. (3) Plasma adiponectin may be a protective factor of coronary heart disease.